Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic

Rozanolixizumab is a fully humanized high‐affinity anti‐human neonatal Fc receptor (FcRn) monoclonal antibody (mAb) that accelerates the removal of circulating immunoglobulin G (IgG), including pathogenic IgG autoantibodies, via the natural lysosomal degradation pathway. The aim of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lledo‐Garcia, Rocio, Dixon, Kate, Shock, Anthony, Oliver, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752106/
https://www.ncbi.nlm.nih.gov/pubmed/34735735
http://dx.doi.org/10.1002/psp4.12739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752106/
https://www.ncbi.nlm.nih.gov/pubmed/34735735
http://dx.doi.org/10.1002/psp4.12739

Ejemplares similares